Roche: to present new data on cancer
(CercleFinance.com) - Roche will present new data on six approved and investigational drugs in ten types of cancer at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, on 2 to 6 June.
Highlights include new data on treatments for lymphoma and hepatocellular carcinoma (HCC), including study results and extended follow-up data for Columvi (glofitamab) of almost two years.
News is expected in the treatment of liver cancer with Tecentriq (atezolizumab) plus Avastin (bevacizumab) with the analysis of patient-reported results from the IMbrave050 study of adjuvant hepatocellular carcinoma (HCC), including quality of life data.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Highlights include new data on treatments for lymphoma and hepatocellular carcinoma (HCC), including study results and extended follow-up data for Columvi (glofitamab) of almost two years.
News is expected in the treatment of liver cancer with Tecentriq (atezolizumab) plus Avastin (bevacizumab) with the analysis of patient-reported results from the IMbrave050 study of adjuvant hepatocellular carcinoma (HCC), including quality of life data.
Copyright (c) 2023 CercleFinance.com. All rights reserved.